Literature DB >> 25316315

Discovery of a novel pyrazole series of group X secreted phospholipase A2 inhibitor (sPLA2X) via fragment based virtual screening.

Hongming Chen1, Laurent Knerr2, Tomas Åkerud3, Kenth Hallberg3, Linda Öster3, Mattias Rohman4, Krister Österlund5, Hans-Georg Beisel5, Thomas Olsson5, Johan Brengdhal5, Jenny Sandmark3, Cristian Bodin3.   

Abstract

The discovery of potent novel pyrazole containing group X secreted phospholipase A2 inhibitors via structure based virtual screening is reported. Docking was applied on a large set of in-house fragment collection and pharmacophore feature matching was used to filter docking poses. The selected virtual screening hits was run in NMR screening, a potent pyrazole containing fragment hit was identified and confirmed by its complex X-ray structure and the following biochemical assay result. Expansion on the fragment hit has led to further improvement of potency while maintaining high ligand efficiency, thus supporting the further development of this chemical series.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  FBLG; Pharmacophore model; Virtual screening; sPLA(2)X inhibitor

Mesh:

Substances:

Year:  2014        PMID: 25316315     DOI: 10.1016/j.bmcl.2014.09.058

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  Structural basis for functional selectivity and ligand recognition revealed by crystal structures of human secreted phospholipase A2 group IIE.

Authors:  Shulin Hou; Tingting Xu; Jinxin Xu; Linbing Qu; Yong Xu; Ling Chen; Jinsong Liu
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

Review 2.  pCRP-mCRP Dissociation Mechanisms as Potential Targets for the Development of Small-Molecule Anti-Inflammatory Chemotherapeutics.

Authors:  Vittorio Caprio; Lina Badimon; Mario Di Napoli; Wen-Hui Fang; Glenn R Ferris; Baoqiang Guo; Rocco S Iemma; Donghui Liu; Yasmin Zeinolabediny; Mark Slevin
Journal:  Front Immunol       Date:  2018-05-28       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.